Table 1.
Test | Company | Method | HPV TARGET | TARGET Region |
HR HPV Genotypes | Validation References | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 18 | 31 | 33 | 35 | 39 | 45 | 51 | 52 | 56 | 58 | 59 | 66 | 68 | ||||||
Hybrid Capture II | Qiagen | Hybridization and signal amplification | DNA | Whole genome |
● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | Gold standard, NTCC study | |
Linear Array HPV Test | Roche | PCR and oligonucleotide hybridization | DNA | L1 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | [8] |
Cobas 4800 HPV Test | Roche | Real Time PCR | DNA | L1 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | [9], ATHENA study |
RealTime High Risk HPV Test | Abbott | Real Time PCR | DNA | L1 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | [10] |
Onclarity HPV Assay | BD | Real Time PCR | DNA | E6 E7 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | [11] |
Anyplex II HPV HR Test | Seegene | TOCE Real Time PCR | DNA | L1 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | [12] |
APTIMA mRNA assay | Hologic | Transcription-Mediated Amplification | mRNA | E6 E7 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | [13] |
in pool | |||||||||||||||||||
in small pool |